Drug intelligence / Profile preview

Ureaderm

Development stage: Unknown
Lead developer: Emcutix Biopharmaceuticals
Administration: Topical

Overview

**Ureaderm** is a commercially launched topical urea-based moisturizing cream range from Emcutix, developed in collaboration with Mantra Pharma. It is available in 10% and 20% urea strengths and uses Multilayer Fatty Acid Emulsion technology to provide sustained urea delivery and prolonged skin hydration. The formulation also includes eicosapentaenoic acid, gamma-linolenic acid, and allantoin to support the epidermal lipid barrier and reduce transepidermal water loss. It is intended for prevention and management of severe dry skin and hyperkeratotic dermatoses, including psoriasis and ichthyosis. ([emcutix.fbmlive.com](https://emcutix.fbmlive.com/press-releases/emcutix-canada-based-mantra-pharma-launch-ureaderm-2/))

Brand names: Ureaderm
Other names: Urea DermUreaDerm

Beyond the preview

Go deeper on Ureaderm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ureaderm.

Explore the full profile